[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572700":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":60,"collaborators":11,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":11,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL",null,[13],"Dietary Supplement: Oral Immunonutrition",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIETARY_SUPPLEMENT","Oral Immunonutrition","Patients receive enteral immunonutrition, Oral Impact® Nestle for 6 weeks from one week before radiotherapy;",[9],[21],{"name":22,"affiliation":5,"role":23},"Weiwei Xiao","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","+86 020 8734 0951","xiaoww@sysucc.org.cn",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Liping Chen","+86 020 87340767","chenlp@sysucc.org.cn",[34,51],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.25,23.11667,{"lat":46,"lon":45},[49],{"name":50,"role":26,"phone":27,"phoneExt":11,"email":28},"WeiWei xiao",{"facility":35,"status":36,"city":37,"state":38,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},{"type":43,"coordinates":53},[45,46],{"lat":46,"lon":45},[56,59],{"name":57,"role":26,"phone":58,"phoneExt":11,"email":28},"Weiwei Xiao, Doctor","＋86-020-87340951",{"name":57,"role":26,"phone":11,"phoneExt":11,"email":11},{"type":23,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"WeiWei Xiao","Chief physician","100572700","oral-immunonutrition-therapy-to-reduce-acute-toxicity-after-neoadjuvant-chemoradiotherapy-pancreatic-cancer-patients-100572700",false,"NCT06736678","Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients","Efficacy of Oral Immunonutrition Therapy in Reducing Acute Toxicity After Neoadjuvant Chemoradiotherapy Among Pancreatic Cancer Patients: a Prospective, Single-arm Clinical Trial","Inclusion Criteria:\n\n* 1\\. Pathologically confirmed pancreatic ductal epithelial malignant tumors;\n* 2\\. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;\n* 3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;\n* 4\\. Age 18 years and older;\n* 5\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 6\\. Expected survival time more than 3 months;\n* 7\\. History of antineoplastic therapy;\n\nExclusion Criteria:\n\n* 1\\. Known allergy or intolerance to any component of investigational Oral Immunonutrition;\n* 2\\. History of Oral Immunonutrition use within one month prior to enrollment;\n* 3\\. Tumor compresses the major duodenal papilla, and \u002For appeared jaundice, acute pancreatitis;\n* 4\\. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;\n* 5\\. Liver, kidney and blood coagulation function failure;\n* 6\\. Patients with hemopathy;\n* 7\\. Patients with active infections;\n* 8\\. Patients with other primary tumor;\n* 9\\. Patients with other medical diseases that seriously affected nutritional status;\n* 10.Subjects deemed by the investigator have other factors that may be ineligible for enrollment;","ALL","18 Years",{"count":73,"type":74},98,"ESTIMATED","INTERVENTIONAL",[77],"NA","A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.",[80,81,82],"Pancreatic Cancer","Neoadjuvant Chemoradiotherapy","Immunonutrition","2024-12-12",{"date":85,"type":86},"2024-12-17","ACTUAL",{"date":88,"type":86},"2024-08-26",{"date":90,"type":74},"2025-09-30",{"name":5,"class":6},2]